Patents Assigned to SBI Biotech Co., Ltd.
  • Methods for suppressing activity of activated interferon-producing cells
    Patent number: 8435530
    Abstract: The present invention provides agents for regulating the activity of interferon-producing cells (IPCs), which comprise as active ingredients antibodies that bind to BST2 and/or to its homologues, and methods for regulating IPC activity that use these antibodies. According to the present invention, the ability of IPCs to produce interferons (IFNs) and the number of cells can be directly regulated. The present invention also provides uses of BST2 and/or its homologues as markers for IPC activation. Compounds that regulate IPC activation can be screened using the markers for IPC activation.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: May 7, 2013
    Assignee: SBI Biotech Co., Ltd.
    Inventors: Jun Ohkawa, Yumiko Kamogawa
  • AZAINDOLE DERIVATIVE
    Publication number: 20120135989
    Abstract: The present invention provides a (di)azaindole derivative represented by the formula (I). A compound of the present invention inhibits a Cdc7 protein kinase activity and suppresses cell proliferation.
    Type: Application
    Filed: June 29, 2011
    Publication date: May 31, 2012
    Applicants: CRYSTALGENOMICS, INC., SBI BIOTECH CO., LTD.
    Inventors: Yoko Funakoshi, Chika Tanaka, Choul Hong Park, Seong Gu Ro
  • Thiazolidinone derivative
    Patent number: 8119812
    Abstract: An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: February 21, 2012
    Assignees: SBI Biotech Co., Ltd., Crystalgenomics, Inc.
    Inventors: Takayuki Irie, Masaaki Sawa, Sayuri Ito, Chika Tanaka, Seong Gu Ro, Choul Hong Park
  • Anti-ILT7 antibody
    Patent number: 8084585
    Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: December 27, 2011
    Assignee: SBI Biotech Co., Ltd.
    Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
  • THIAZOLIDINONE DERIVATIVE
    Publication number: 20110190299
    Abstract: An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.
    Type: Application
    Filed: April 19, 2010
    Publication date: August 4, 2011
    Applicants: SBI BIOTECH CO., LTD., CRYSTALGENOMICS, INC.
    Inventors: Takayuki Irie, Masaaki Sawa, Sayuri Ito, Chika Tanaka, Seong Gu Ro, Choul Hong Park